Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
66 hedge funds and large institutions have $14.6M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 8 increasing their positions, 28 reducing their positions, and 22 closing their positions.
7% less funds holding
Funds holding: 71 → 66 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
34% less capital invested
Capital invested by funds: $22.2M → $14.6M (-$7.6M)
71% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$580K |
| 2 |
RC
RBF Capital
San Francisco,
California
|
+$402K |
| 3 |
Millennium Management
New York
|
+$304K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$166K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.92M |
| 2 |
State Street
Boston,
Massachusetts
|
-$709K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$419K |
| 4 |
Renaissance Technologies
New York
|
-$407K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$363K |
EIGR Hedge Fund Activity: Q2 2023 in Review
66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2023, worth a combined $14.6M — down 34% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EIGR and 17 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 8 added.
The largest buyer was Ameriprise, adding an estimated $580K. The largest seller was BlackRock, cutting an estimated $1.92M.
- 66 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2023, down from 71 in Q1 2023.
- Funds reported $14.6M of Eiger BioPharmaceuticals, Inc. stock for Q2 2023, down 34% quarter-over-quarter.
- 17 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2023 and 22 closed out, a net change of -5 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2023 was Ameriprise, an estimated $580K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2023 was BlackRock, an estimated $1.92M sold.
Based on aggregated 13F filings for Q2 2023.